4//SEC Filing
Arbuckle Stuart A 4
Accession 0000875320-25-000009
CIK 0000875320other
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 4:18 PM ET
Size
7.4 KB
Accession
0000875320-25-000009
Insider Transaction Report
Form 4
Arbuckle Stuart A
EVP\Chief Commercial Officer
Transactions
- Award
Common Stock
2025-02-04+14,624→ 64,315 total - Award
Common Stock
2025-02-04+8,448→ 72,763 total
Holdings
- 140(indirect: By 401(k))
Common Stock
Footnotes (2)
- [F1]Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.
- [F2]Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001557290
Filing Metadata
- Form type
- 4
- Filed
- Feb 5, 7:00 PM ET
- Accepted
- Feb 6, 4:18 PM ET
- Size
- 7.4 KB